bioMerieux to Develop New Highly-Specific, Non-Invasive Test for Prostate Cancer, Reducing Unnecessary Biopsies
29-Sep-2008 -
bioMérieux has signed a license and development agreement with the German biotechnology company, ProteoSys, for Annexin 3, which will be used to develop a urine-based, confirmatory diagnostic test for prostate cancer. After a research phase, the new test should be developed on the VIDAS® ...
biology
biotechnology
diagnostic tests
+4